| Louise Breakstone, MD | |
|
610 Wyoming Ave, Kingston, PA 18704-3702 | |
| (570) 288-5441 | |
| Not Available |
| Full Name | Louise Breakstone |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 41 Years |
| Location | 610 Wyoming Ave, Kingston, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831126010 | NPI | - | NPPES |
| 001136676 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD031688E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wilkes-barre General Hospital | Wilkes-barre, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Commonwealth Physician Network Llc | 2668696592 | 84 |
News Archive
The Montreal Neurological Institute of McGill University, a world-leading institution focused on brain research and advanced patient care, and Thermo Fisher Scientific, the world leader in serving science, today announce an agreement designed to accelerate the understanding of neurological disease by focusing on about 30 proteins associated with Parkinson's disease, amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegias, epileptic encephalopathies and ataxias, which are all devastating brain diseases.
The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease. Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them possible were versatile enough to knock out a wide range of deadly bacterial threats.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive, fatal neurological disease that attacks the nerve cells controlling voluntary muscles. No effective treatments have been found.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst.
› Verified 5 days ago
| Entity Name | Commonwealth Physician Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003238635 PECOS PAC ID: 2668696592 Enrollment ID: O20140617000549 |
News Archive
The Montreal Neurological Institute of McGill University, a world-leading institution focused on brain research and advanced patient care, and Thermo Fisher Scientific, the world leader in serving science, today announce an agreement designed to accelerate the understanding of neurological disease by focusing on about 30 proteins associated with Parkinson's disease, amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegias, epileptic encephalopathies and ataxias, which are all devastating brain diseases.
The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease. Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them possible were versatile enough to knock out a wide range of deadly bacterial threats.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive, fatal neurological disease that attacks the nerve cells controlling voluntary muscles. No effective treatments have been found.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Louise Breakstone, MD 610 Wyoming Ave, Kingston, PA 18704-3702 Ph: (570) 288-5441 | Louise Breakstone, MD 610 Wyoming Ave, Kingston, PA 18704-3702 Ph: (570) 288-5441 |
News Archive
The Montreal Neurological Institute of McGill University, a world-leading institution focused on brain research and advanced patient care, and Thermo Fisher Scientific, the world leader in serving science, today announce an agreement designed to accelerate the understanding of neurological disease by focusing on about 30 proteins associated with Parkinson's disease, amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegias, epileptic encephalopathies and ataxias, which are all devastating brain diseases.
The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease. Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them possible were versatile enough to knock out a wide range of deadly bacterial threats.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive, fatal neurological disease that attacks the nerve cells controlling voluntary muscles. No effective treatments have been found.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst.
› Verified 5 days ago
Dr. Anthony Giardina, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 349 Pierce St, Kingston, PA 18704 Phone: 570-288-2300 Fax: 570-288-2298 | |
Danita Renelsa Fox, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Sharpe Street, Kingston, PA 18704 Phone: 570-552-8966 Fax: 570-552-8958 | |
Dr. Brent Keen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 499 Wyoming Ave, Kingston, PA 18704 Phone: 570-714-3050 Fax: 570-714-3051 | |
Dr. Michael E. Kordek, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 499 Wyoming Ave, Kingston, PA 18704 Phone: 570-283-2161 Fax: 570-714-0670 | |
Soohan Mansuri, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 511 Pierce St, Kingston, PA 18704 Phone: 570-714-3333 Fax: 570-338-3993 | |
Dr. Jason Scotti, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Sharpe St, Kingston, PA 18704 Phone: 570-491-0126 Fax: 570-230-0013 | |
Dr. Maureen M Litchman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Sharpe Street, Kingston, PA 18704 Phone: 570-552-8900 Fax: 570-552-8958 |